-
Shire Development LLC et al v. Teva Pharmaceuticals USA, Inc. et al DC
- 1:17-cv-01696
- D. Del.
- Filed: 11/22/2017
- Closed: 11/08/2019
- Latest Docket Entry: 11/08/2019
- Judge: Richard G. Andrews
+1
- PACER
3
Plaintiffs
5
Defendants
4
Accused
Products
3
Patents-in-Suit
717
Days in
Litigation
-
Shire Development LLC et al v. Teva Pharmaceuticals USA, Inc. et al DC
- 1:17-cv-01696
- D. Del.
- Filed: 11/22/2017
- Closed: 11/08/2019
- Latest Docket Entry: 11/08/2019
- Judge: Richard G. Andrews
+1
- PACER
Cause of Action
Infringement
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
-
Infringement
Impax Laboratories, LLC
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Amphetamine extended-release capsules 12.5 mg Amphetamine extended-release capsules 25 mg Amphetamine extended-release capsules 37.5 mg Amphetamine extended-release capsules 50 mg | US 6,913,768 B2 | All Asserted Claims |
Infringement
Entry 202
|
| Amphetamine extended-release capsules 12.5 mg Amphetamine extended-release capsules 25 mg Amphetamine extended-release capsules 37.5 mg Amphetamine extended-release capsules 50 mg | US 8,846,100 B2 | All Asserted Claims |
Infringement
Entry 202
|
| Amphetamine extended-release capsules 12.5 mg Amphetamine extended-release capsules 25 mg Amphetamine extended-release capsules 37.5 mg Amphetamine extended-release capsules 50 mg | US 9,173,857 B2 | All Asserted Claims |
Infringement
Entry 202
|
SpecGx LLC
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Amphetamine extended-release capsules 12.5 mg Amphetamine extended-release capsules 25 mg Amphetamine extended-release capsules 37.5 mg Amphetamine extended-release capsules 50 mg | US 6,913,768 B2 | All Asserted Claims |
Infringement
Entry 103
|